TXNRD1 and hepatocellular carcinoma: MiR-328-3p acts as a tumor suppressor in HCC by inhibiting thioredoxin reductase 1 (TXNRD1), suggesting that it is a potential target for the clinical treatment of HCC (Li et al., 2019).